Last reviewed · How we verify

Prevention of NSAID-Induced Gastric Ulcer — Treatment Landscape & Competitive Intelligence

Prevention of NSAID-Induced Gastric Ulcer (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of NSAID-Induced Gastric Ulcer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Nexium esomeprazole AstraZeneca Proton pump inhibitor (PPI) Potassium-transporting ATPase 2001-02-20
Cytotec misoprostol Generic (originally Searle/Pfizer) Prostaglandin E1 analog Prostaglandin E2 receptor EP2 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin E2 receptor EP4 subtype 1988-12-27

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. AstraZeneca · 1 drug in Prevention of NSAID-Induced Gastric Ulcer
  2. Generic (originally Searle/Pfizer) · 1 drug in Prevention of NSAID-Induced Gastric Ulcer
  3. Pfizer · 1 drug in Prevention of NSAID-Induced Gastric Ulcer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of NSAID-Induced Gastric Ulcer:

Cite this brief

Drug Landscape (2026). Prevention of NSAID-Induced Gastric Ulcer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-nsaid-induced-gastric-ulcer. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing